STAAR Surgical Company (STAA) - Total Assets

Latest as of December 2025: $461.62 Million USD

Based on the latest financial reports, STAAR Surgical Company (STAA) holds total assets worth $461.62 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check STAAR Surgical Company cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

STAAR Surgical Company - Total Assets Trend (1988–2025)

This chart illustrates how STAAR Surgical Company's total assets have evolved over time, based on quarterly financial data. Explore STAAR Surgical Company long-term investment allocation to see how much of total assets are deployed in long-term investments.

STAAR Surgical Company - Asset Composition Analysis

Current Asset Composition (December 2025)

STAAR Surgical Company's total assets of $461.62 Million consist of 67.5% current assets and 32.5% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 33.2%
Accounts Receivable $54.61 Million 11.8%
Inventory $55.50 Million 12.0%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $30.70 Million 6.7%
Goodwill $1.79 Million 0.4%

Asset Composition Trend (1988–2025)

This chart illustrates how STAAR Surgical Company's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see STAAR Surgical Company stock valuation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: STAAR Surgical Company's current assets represent 67.5% of total assets in 2025, an increase from 38.5% in 1988.
  • Cash Position: Cash and equivalents constituted 33.2% of total assets in 2025, up from 0.6% in 1988.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 1988.
  • Asset Diversification: The largest asset category is inventory at 12.0% of total assets.

STAAR Surgical Company Competitors by Total Assets

Key competitors of STAAR Surgical Company based on total assets are shown below.

Company Country Total Assets
Andon Health Co Ltd
SHE:002432
China CN¥29.91 Billion
AVE Science & Technology Co Ltd
SHG:688067
China CN¥611.46 Million
MEDIMI AB AK
F:79T
Germany €1.70 Million
Ansell Ltd
AU:ANN
Australia AU$3.33 Billion
Nanosonics Ltd
AU:NAN
Australia AU$279.25 Million
SDI Ltd
AU:SDI
Australia AU$135.84 Million
Austco Healthcare Ltd
AU:AHC
Australia AU$91.07 Million
Trajan Group Holdings Ltd
AU:TRJ
Australia AU$192.32 Million

STAAR Surgical Company - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 4.55 5.23 6.19
Quick Ratio 3.74 4.62 5.72
Cash Ratio 0.00 0.00 0.00
Working Capital $243.04 Million $297.63 Million $187.39 Million

STAAR Surgical Company - Advanced Valuation Insights

This section examines the relationship between STAAR Surgical Company's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.86
Latest Market Cap to Assets Ratio 3.00
Asset Growth Rate (YoY) -9.4%
Total Assets $461.62 Million
Market Capitalization $1.39 Billion USD

Valuation Analysis

Premium Asset Valuation: The market values STAAR Surgical Company's assets at a significant premium (3.00x), suggesting investors see substantial growth potential or unique competitive advantages.

Significant Asset Reduction: STAAR Surgical Company's assets decreased by 9.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for STAAR Surgical Company (1988–2025)

The table below shows the annual total assets of STAAR Surgical Company from 1988 to 2025.

Year Total Assets Change
2025-12-31 $461.62 Million -9.40%
2024-12-31 $509.52 Million +4.26%
2023-12-31 $488.69 Million +16.68%
2022-12-31 $418.82 Million +21.12%
2021-12-31 $345.78 Million +34.33%
2020-12-31 $257.42 Million +24.04%
2019-12-31 $207.52 Million +24.01%
2018-12-31 $167.34 Million +146.33%
2017-12-31 $67.93 Million +3.80%
2016-12-31 $65.44 Million +3.95%
2015-12-31 $62.95 Million +6.86%
2014-12-31 $58.91 Million -4.88%
2013-12-31 $61.93 Million +13.10%
2012-12-31 $54.76 Million +11.74%
2011-12-31 $49.01 Million +20.75%
2010-12-31 $40.59 Million -30.84%
2009-12-31 $58.68 Million +11.60%
2008-12-31 $52.58 Million -2.95%
2007-12-31 $54.18 Million +13.42%
2006-12-31 $47.77 Million -9.45%
2005-12-31 $52.76 Million +1.50%
2004-12-31 $51.97 Million +10.07%
2003-12-31 $47.22 Million +4.42%
2002-12-31 $45.22 Million -31.28%
2001-12-31 $65.81 Million -17.90%
2000-12-31 $80.15 Million -6.03%
1999-12-31 $85.30 Million +16.37%
1998-12-31 $73.30 Million +17.47%
1997-12-31 $62.40 Million +22.11%
1996-12-31 $51.10 Million +31.70%
1995-12-31 $38.80 Million +34.26%
1994-12-31 $28.90 Million +53.72%
1993-12-31 $18.80 Million +46.88%
1992-12-31 $12.80 Million +36.17%
1991-12-31 $9.40 Million -11.32%
1990-12-31 $10.60 Million -20.30%
1989-12-31 $13.30 Million -17.39%
1988-12-31 $16.10 Million --

About STAAR Surgical Company

NASDAQ:STAA USA Medical Instruments & Supplies
Market Cap
$1.45 Billion
Market Cap Rank
#7709 Global
#2239 in USA
Share Price
$29.22
Change (1 day)
+1.04%
52-Week Range
$16.10 - $33.34
All Time High
$162.68
About

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorde… Read more